A Randomized Controlled Pilot Trial of Azithromycin or Artesunate Added to Sulfadoxine-Pyrimethamine as Treatment for Malaria in Pregnant Women
Open Access
- 14 November 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (11), e1166
- https://doi.org/10.1371/journal.pone.0001166
Abstract
New anti-malarial regimens are urgently needed in sub-Saharan Africa because of the increase in drug resistance. We investigated the safety and efficacy of azithromycin or artesunate combined with sulfadoxine-pyrimethamine used for treatment of malaria in pregnant women in Blantyre, Malawi. This was a randomized open-label clinical trial, conducted at two rural health centers in Blantyre district, Malawi. A total of 141 pregnant women with uncomplicated Plasmodium falciparum malaria were recruited and randomly allocated to 3 treatment groups: sulfadoxine-pyrimethamine (SP; 3 tablets, 500 mg sulfadoxine and 25 mg pyrimethamine per tablet); SP plus azithromycin (1 g/day×2 days); or SP plus artesunate (200 mg/day×3 days). Women received two doses administered at least 4 weeks apart. Heteroduplex tracking assays were performed to distinguish recrudescence from new infections. Main outcome measures were incidence of adverse outcomes, parasite and fever clearance times and recrudescence rates. All treatment regimens were well tolerated. Two women vomited soon after ingesting azithromycin. The parasite clearance time was significantly faster in the SP-artesunate group. Recrudescent episodes of malaria were less frequent with SP-azithromycin [Hazard Ratio 0.19 (95% confidence interval 0.06 to 0.63)] and SP-artesunate [Hazard Ratio 0.25 (95% confidence interval 0.10 to 0.65)] compared with SP monotherapy. With one exception (an abortion in the SP-azithromycin group), all adverse pregnancy outcomes could be attributed to known infectious or obstetrical causes. Because of the small sample size, the effect on birth outcomes, maternal malaria or maternal anemia could not be evaluated. Both SP-artesunate and SP-azithromycin appeared to be safe, well tolerated and efficacious for the treatment of malaria during pregnancy. A larger study is needed to determine their safety and efficacy in preventing poor birth outcomes. ClinialTrials.gov NCT00287300Keywords
This publication has 46 references indexed in Scilit:
- Estimating True Antimalarial Efficacy by Heteroduplex Tracking Assay in Patients with Complex Plasmodium falciparum InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Randomized Trial of 2‐Dose versus Monthly Sulfadoxine‐Pyrimethamine Intermittent Preventive Treatment for Malaria in HIV‐Positive and HIV‐Negative Pregnant Women in MalawiThe Journal of Infectious Diseases, 2006
- Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective studyBMJ, 2004
- Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997–1999Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- The Safety of Antimalarial Drugs in PregnancyDrug Safety, 1996
- New Ballard Score, expanded to include extremely premature infantsThe Journal of Pediatrics, 1991
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982